The success of clinical trials in Wilms' tumor over the past 30 years has led to an overall survival of 85%, and treatment-related morbidity has been reduced with less aggressive chemotherapeutic regimens for patients with validated good prognostic factors, such as low stage and favorable histology. It is becoming increasingly apparent that treatment can be optimized through stratification of patients according to tumor stage and histology. This article discusses the most debated issues and advances that have been made in the management of Wilms' tumor.
- Lyndon M Gommersall
- Manit Arya
- Patrick Duffy